Gilead Sciences (GILD +0.9%) will be hustling to produce sufficient quantities of antiviral remdesivir after the expected nod from regulators after two successful trials in COVID-19 patients.
It started with an inventory of ~5K doses when
studies ramped up and now has ~50K which should fly off the shelves as
soon as emergency use is authorized. It says its goal is to have
“multiple millions” of courses by year-end.
Production is apparently no walk in the park,
involving a series of chemical steps, a range of components and manual
inspection of each filled vial, the last a labor-intensive step
considering the volumes planned. It has been procuring raw materials for
some time and has condensed the manufacturing process to 6-8 months
from 9-12 months.
Initial quantities will be generally reserved for seriously ill patients.
https://seekingalpha.com/news/3567039-gilead-to-be-challenged-to-meet-demand-for-remdesivir
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.